PI3K/AKT/mTOR pathway is frequently activated in TNBC, through gain of function mutation of PI3KCA and of loss of function of PTEN [8, 57], and, therefore, the pharmacological inhibition of PI3K/AKT pathway can, in theory, represent a successful treatment strategy in these tumours [58]. This evidence concerns the gene AKT1 and neoplasm.